|
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
|
01 April 2019 |
|
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
|
27 March 2019 |
|
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
|
15 March 2019 |
|
Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
|
11 March 2019 |
|
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
|
04 March 2019 |
|
Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
|
18 February 2019 |
|
Sandoz and Pear Therapeutics announce US launch of reSET-OTM to help treat Opioid Use Disorder
|
07 January 2019 |
|
Novartis receives European Commission approval for self-administration of Xolair® across all indications
|
13 December 2018 |
|
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
|
27 November 2018 |
|
Novartis rises to second place in 2018 Access to Medicine Index
|
21 November 2018 |